RA
KRYS icon

Royce & Associates’s Krystal Biotech KRYS Stock Holding History

Royce & Associates’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-22,000
Closed -$1.15M – 997
2021
Q3 		$1.15M Hold
22,000
– – 0.01% 803
2021
Q2 		$1.5M Hold
22,000
– – 0.01% 799
2021
Q1 		$1.7M Buy
+22,000
New +$1.6M 0.01% 782

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates's KRYS Position: Q4 2021 in Review

Royce & Associates sold out of Krystal Biotech (KRYS) in Q4 2021, closing a stake of 22,000 shares — an estimated $1.15M sold.

Royce & Associates first reported a position in KRYS in Q1 2021 and held it in 3 quarters. The position peaked at $1.7M in Q1 2021. 140 funds tracked by Wall St. Rank hold KRYS as of Q4 2021.

  • Royce & Associates reported no remaining Krystal Biotech position as of Q4 2021 after selling out during the quarter.
  • Royce & Associates sold 22,000 Krystal Biotech shares in Q4 2021, an estimated $1.15M.
  • Royce & Associates first reported a position in Krystal Biotech in Q1 2021 and held it in 3 quarters.
  • Royce & Associates's Krystal Biotech position peaked at $1.7M in Q1 2021.
  • 140 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2021.

Based on Royce & Associates's 13F filing for Q4 2021, filed 7 Feb 2022.